Objective: To examine baseline psychological functioning and antiepileptic drug (AED) behavioral side effects in new onset epilepsy and determine, by age, whether baseline psychological functioning predicts AED behavioral side effects 1 month following AED initiation. Methods: A retrospective chart review was conducted between July 2011 and December 2014 that included youths with new onset epilepsy. As part of routine interdisciplinary care, caregivers completed the Behavior Assessment System for Children, 2nd Edition: Parent Rating Scale to report on baseline psychological functioning at the diagnostic visit and the Pediatric Epilepsy Side Effects Questionnaire to identify AED behavioral side effects at the 1-month follow-up clinic visit following AED initiation. Children (age = 2-11 years) and adolescents (age = 12-18 years) were examined separately.
| INTRODUCTION
Epilepsy treatment aims to optimize seizure control, minimize antiepileptic drug (AED) side effects, and improve health-related quality of life. 1 The prevalence of emotional (8%-25% depression [2] [3] [4] ; 17%-63% anxiety 2, 4, 5 ) and behavioral (30%-40% attention deficit hyperactivity disorder [ADHD] 6 ) symptoms are common in epilepsy, with multifactorial etiologies, including neurobiological, psychosocial, and iatrogenic risk factors. Comorbid psychological symptoms and AED side effects can be difficult to differentiate and have a significant impact on prognosis 7 and clinical decision making. 8 In effect, psychological comorbidities may be confused for AED behavioral side effects and lead to unnecessary AED changes, which in turn can compromise seizure control. Psychological screening prior to AED initiation establishes baseline psychological functioning, allows for more precise AED side effect identification, and may guide treatment decision making. Prior to seizure onset, approximately one-third of youths with epilepsy experience impairing symptoms of depression, anxiety, somatic complaints, and inattention. 9 The clinical presentation becomes more complex when an AED is initiated to control seizures. Although well documented in adults, AED side effect tolerability is understudied in children and adolescents. 10, 11 Notably, cognitive side effects (eg, fatigue, cognitive slowing) have been documented for older generation AEDs (eg, phenobarbital, valproic acid) and behavioral side effects (eg, irritability, aggression) for newer generation AEDs (eg, levetiracetam, gabapentin). 11, 12 Levetiracetam is known to have an adverse behavioral side effect profile, with general behavioral problems (19%) and irritability (2.6%) noted in monotherapy, [12] [13] [14] [15] and irritability (4.7%), hyperexcitability (4.4%), and aggression (2.7%) noted in adjunctive use. 16 To date, predictors of AED behavioral side effect tolerability in pediatric epilepsy is not well established. 11 In adults with new onset epilepsy, the presence of a psychiatric history, specifically symptoms of impulsivity, aggression, depression, and anxiety, has been linked to higher AED adverse effects. 11, [17] [18] [19] Stages of development may impact the manifestation of AED behavioral side effects in pediatric epilepsy. Given their limited verbal abilities, toddlers and preschoolers may exhibit adverse behavioral side effects by demonstrating aggressive and impulsive behaviors (eg, hitting) versus verbalizing symptoms of depression and anxiety. In contrast, adolescents may exhibit similar aggressive and impulsive behaviors, but they may present also with reduced frustration tolerance, emotional lability, verbal outbursts, and irritability, which are common symptoms of depression and anxiety. 13, 14 Disentangling developmental misbehavior, baseline psychological comorbidities, and behavioral side effects can be challenging. When side effects become intolerable, providers switch AEDs. Unfortunately, AED changes may be at the expense of good seizure control and limit the use of otherwise efficacious AEDs. Identification of clinical features that could predict increased risk of AED behavioral side effects could improve AED selection and tolerance in children and adolescence. The current study aimed to inform these clinical challenges by assessing baseline psychological functioning prior to epilepsy diagnosis in pediatric epilepsy, along with using baseline data to identify potential risk factors for AED behavioral side effects using standardized measures. The intended focus was to strategically inform clinical practice when differentiating epilepsy comorbidities with reported AED behavioral side effects. We examined baseline psychological functioning and AED behavioral side effects in new onset epilepsy and determined, by age, whether baseline psychological functioning predicts AED behavioral side effects 1 month following AED initiation. Baseline symptoms of hyperactivity/impulsivity, aggression, depression, and anxiety were specifically chosen based on the literature. [12] [13] [14] [15] [16] We hypothesized that (1) levetiracetam would have significantly higher AED behavioral side effects compared to other AEDs; and (2) hyperactivity/impulsivity and aggression would significantly predict AED behavioral side effects in children and adolescents, along with depression and anxiety for adolescents.
| MATERIALS AND METHODS

| Standard protocol, approvals, registrations, and patient consents
The institutional review board approved retrospective medical chart data extraction for this study.
Key Points
• If patients are diagnosed with epilepsy, an AED is prescribed at the diagnostic visit and patients are then followed by a specialist nurse practitioner. Upon diagnosis, the epileptologist provides education on the need to monitor psychological comorbidities in children and adolescents and administers the Behavior Assessment System for Children, 2nd Edition: Parent Rating Scale (BASC-2: PRS) 20 to obtain baseline psychological functioning prior to AED initiation. Notably, the BASC-2: PRS was administered at the same time as selection of the AED, and thus results of the BASC-2: PRS did not influence AED selection. Additionally, our team has established practice patterns of prescribing AEDs based upon diagnoses. 21 Follow-up visits occur 1 month postdiagnosis and every 3 months thereafter with coinciding safety laboratory tests. Biannual psychology visits with a clinical psychologist address adjustment to epilepsy, psychosocial comorbidities, AED adherence, and other salient issues (eg, reinforce seizure safety, sleep hygiene, stress management). At the 1-month follow-up, the Pediatric Epilepsy Side Effects Questionnaire (PESQ) 22 is reviewed with the family by the specialist nurse practitioner. The BASC-2: PRS is then reviewed by the clinical psychologist to identify areas of psychological concern prior to AED initiation. Providers use the BASC-2: PRS to determine baseline psychological comorbidities and the PESQ to assess for AED side effects. When behavioral concerns are reported by caregivers at the initial follow-up visit (approximately 1 month after AED initiation), these data are taken together to ascertain a timeline of potential causes of behavioral concerns, such as AED behavioral side effects, baseline psychological functioning, seizures, or poor adjustment. If providers and family believe adverse behavioral side effects are present, as they are not attributable to baseline psychological symptoms, then the AED or dose is modified following the 1-month follow-up visit to rectify concerns around intolerable side effects.
| Measures
| BASC-2: PRS
The BASC-2: PRS 20 is a 134-to 160-item parent report measure of behavioral and personality in youths across 3 age groups: preschool (2-5 years), child (6-11 years), and adolescent (12-21 years). Depending on the age group, the BASC-2: PRS yields 4-5 composite scales (eg, Internalizing Problems, Externalizing Problems, Behavioral Symptoms Index, School Program, and Adaptive Skills). The measure yields T scores for which scores of 60-69 are considered "at risk" and indicate behaviors that may warrant clinical attention and evaluation; T scores ≥ 70 suggest clinical elevations and represent a high level of maladjustment. Internal reliability for the BASC-2: PRS ranges from 0.58 to 0.89 and has demonstrated reliability and validity in pediatric epilepsy populations. [23] [24] [25] The Hyperactivity, Aggression, Depression, and Anxiety subscales were used to capture main study variables.
| PESQ
The PESQ 22 is a 19-item parent report measure of AED side effects in cognitive, motor, behavior, general neurological, and weight domains. Items are summed and transformed into a score ranging from 0 to 100, with higher scores representing more side effects. The PESQ has strong internal consistency (0.72-0.93) and test-retest reliability (0.74-0.97). 22 The PESQ Behavior Scale was used to assess AED behavioral side effects and has good internal consistency (0.81) and test-retest reliability (0.82; M = 12.9, standard deviation = 21.0). 22 
| Medical chart review
Two trained clinical research coordinators extracted demographic and clinical data through chart review. Clinical data included: AED, epilepsy classification, baseline psychological functioning (BASC-2: PRS), and AED side effects (PESQ).
| Statistical analysis
Descriptive analyses, including means, standard deviations, and frequencies, were used to examine demographic and medical variables, as well as outcomes of interest. The sample was dichotomized into 2 age groups: 2-to 11-yearolds (children) and 12-to 18-year-olds (adolescents). Due to missing PESQ data, our sample sizes were reduced for analyses involving AED side effect data. Analyses of variance were conducted to examine AED behavioral side effects by age and AED. To ensure measurement of unique constructs, correlations were conducted between BASC-2: PRS identified subscales and PESQ Behavioral Scale. Parallel hierarchical linear regression analyses based upon age groups were then conducted to determine whether baseline psychological functioning (BASC-2: PRS) prior to AED initiation predicted AED behavioral side effects (PESQ) 1 month following AED initiation, after controlling for patient sex and prescribed AED. Due to the high correlation (Cramer V = 0.95, P < .0001) between initial AED and seizure type (ie, localized, generalized, unclassified), only the AED was retained in the analyses. For children, predictor variables in the model included the Hyperactivity and Aggression subscales of the BASC-2: PRS. For adolescents, predictor variables in the model included the Hyperactivity, Aggression, Anxiety, and Depression subscales of the BASC-2: PRS. For significant variables identified in the regression, analyses of variance were conducted to examine group differences based on BASC-2: PRS clinical cutoffs on AED behavioral side effects.
3 | RESULTS
| Participants
Participants included 380 children and adolescents with epilepsy. The sample size was reduced to 335 children (n = 249) and adolescents (n = 86) for analyses examining AED behavioral side effects. Mean age was 8.9 AE 4.3 years with an average of 1.5 AE 1.2 months since diagnosis. Fifty percent of the sample was male. Eighty-two percent selfidentified as white: non-Hispanic, 11% black, 1.5% white: Hispanic, 1.5% bi-/multiracial, 1% Asian, and 3% other. Forty-two percent of participants were diagnosed with generalized epilepsy (39% idiopathic, 1% symptomatic, 2% cryptogenic), 35% of participants with focal epilepsy (20% idiopathic, 4% symptomatic, 11% cryptogenic), and 23% with unclassified epilepsy (22% idiopathic, 0.3% symptomatic, 1% cryptogenic). In the total sample, 26% had known syndromes (17% childhood absence epilepsy, 4% juvenile myoclonic epilepsy, 5% benign rolandic epilepsy, and 1% other). Patients were initiated on the following AEDs: 37% levetiracetam, 21% carbamazepine, 19% ethosuximide, 18% valproate, 6% oxcarbazepine. Sixty-one percent of the participants had private insurance, 37% had public insurance, and 2% were self-pay patients. Insurance type was a proxy for socioeconomic status. 26 
| Baseline psychological symptoms
Seventy percent of youths had at-risk or clinical elevations on at least 1 subscale (see Figure 1) . Figure 2 ). Behavioral side effects were also significantly worse for levetiracetam (M = 22.41 AE 2.2, P < .0001) and carbamazepine (M = 16.3 AE 3.4, P < .05) compared to ethosuximide (M = 10.3 AE 5.0). A significant difference in behavioral side effects was not detected between levetiracetam and carbamazepine.
| Predictors of AED behavioral side effects
Low positive correlations were detected between BASC-2: PRS identified subscales and PESQ Behavioral Scale (Cramer V = 0.12-0.23, P < .00). First, a hierarchical regression analysis was used to identify significant predictors of behavioral side effects in preschool and school-aged children with epilepsy (see Table 1 ). Child sex was entered at
Step 1, explaining 2% of the variance in behavioral side effects. An additional 3% of variance was accounted for by AED in Step 2. In the final step, BASC-2: PRS Aggression and Hyperactivity subscales accounted for an additional 7% of variance, which resulted in a significant model (R 2 = 0.098, adjusted R 2 = 0.07, F 2,244 = 6.6, P < .0001;
see Table 1 ). The only significant predictor in the final model was the BASC-2: PRS Hyperactivity subscale (b = .29, P < .01), with baseline hyperactivity/impulsivity predicting higher behavioral side effects. Next, similar analyses were conducted to identify predictors of behavioral side effects in adolescents with GUILFOYLE ET AL.
epilepsy (see Table 2 ). In Step 1, child sex accounted for little variance in the model (<1%). Similarly, AED in Step 2 added little additional variance (3%). In the final step, BASC-2: PRS Hyperactivity, Aggression, Anxiety, and Depression subscales were added. The final model was significant and accounted for an additional 19% of variance (R 2 = 0.19, adjusted R 2 = 0.13, F 4,79 = 3.1, P < .01; see Table 2 ). The only significant predictor in the final model was BASC-2: PRS Hyperactivity subscale (b = .41, P < .01), with higher baseline hyperactivity/impulsivity predicting higher behavioral side effects. Additional analyses were conducted to examine whether youths who were at risk (T scores = 60-69) or clinically elevated (T scores ≥ 70) on the BASC-2: PRS Hyperactivity subscale had higher behavioral side effects compared to children with scores within normal limits (T scores < 60).
F I G U R E 1 Baseline psychological functioning at-risk and clinical elevations (N = 380)
F I G U R E 2 Differences in behavioral side effects based on antiepileptic drugs 150 | Analyses of variance were conducted separately by age group. For the younger cohort, a significant difference was found on behavioral side effects based on whether children were within normal limits, at risk, or clinically elevated on the BASC-2: PRS Hyperactivity scale, F 2,246 = 8.6, P < .001 (see Figure 3) . Post hoc analyses revealed that children within normal limits on the BASC-2: PRS Hyperactivity subscale had significantly lower behavioral side effects 1 month following AED initiation (M = 21.4 AE 1.9) compared to those at risk (M = 32.1 AE 3.6, P < .01) or clinically elevated (M = 40.0 AE 5.2, P < .001). For adolescents, a significant difference was found on behavioral side effects based on clinical cutoffs on the BASC-2: PRS Hyperactivity subscale, F 2,83 = 7.5, P < .001. Post hoc analyses revealed that adolescents within normal limits on the BASC-2: PRS Hyperactivity subscale had significantly lower behavioral side effects 1 month following AED initiation (M = 8.8 AE 14.07) compared to those at risk (M = 25.3 AE 21.3, P < .01) or clinically elevated (M = 26.7 AE 23.4, P < .01; see Figure 3 ). No differences were found between at risk and clinically elevated groups for either preschool/school-aged children or adolescents.
| DISCUSSION
The current study examined an innovative, standardized approach to assessing and interpreting caregiver-reported AED behavioral side effects in the context of baseline psychological functioning in youths with new onset epilepsy. Baseline hyperactivity/impulsivity across all youths predicted greater AED behavioral side effects 1 month following treatment initiation, even after controlling for patient age and AED. Younger children were noted to have significantly higher AED behavioral side effects compared to adolescents. Although levetiracetam is reputed to have more challenging behavioral side effects, our data indicates that valproic acid had the greatest AED behavioral side effects. Findings shed new light on how AED behavioral side effects should be interpreted in the context of baseline psychological functioning to guide clinical decision making, particularly when balancing AED side effects with efficacy. Assessing baseline psychological functioning in youths with new onset epilepsy is a novel approach to understanding the role of psychological comorbidities in the clinical presentation of AED side effects. Across all areas of functioning, moderate to clinical psychological elevations were detected in 70% of the sample prior to AED initiation, highlighting the high prevalence of psychological symptoms that predate and/or co-occur with epilepsy as seen in prior studies. 9 At epilepsy onset, providers should screen for psychological comorbidities, particularly symptoms of hyperactivity/impulsivity, which was exhibited in 28% of the sample, and refer for psychological services when indicated to optimize quality of life. Baseline data are often informative throughout the course of epilepsy treatment. 8 Broadly, younger children, across all AEDs, had more difficulty with behavioral side effects compared to adolescents. Although levetiracetam has been implicated as producing worse mood and behavioral side effects in both youths and adults, [12] [13] [14] [15] our study highlights that valproic acid behavioral side effects may be more problematic than initially expected in younger children, even beyond levetiracetam behavioral side effects. However, the difference between valproic acid and levetiracetam was not significant. Furthermore, levetiracetam and carbamazepine had similar rates of behavioral side effects. Based on the minimally clinically important difference scores of 8.05, 27 these differences by drug and age are perceived to be important by caregivers. Although understudied, 11 caregivers reported the fewest behavioral side effects with ethosuximide across all age groups. Providers can guide families about managing AED behavioral side effects to improve tolerability at AED initiation and may optimize seizure control. Specific anticipatory strategies include psychoeducation on (1) the importance of establishing consistent eating and sleep routines; (2) identification of higher risk settings/situations associated with emotional reactivity (eg, parent limit setting, overstimulation); and (3) proactive, effective behavioral management strategies, such as child removal from situations at the first sign of distress and reinforcing desired behaviors (eg, use of relaxation strategies to promote emotion regulation). Behavioral management strategies around these areas have proven efficacy.
28,29
The BASC-2: PRS Hyperactivity Scale captures underlying symptoms of behavioral disinhibition, such as items related to self-control, interrupting others, tantrums, not thinking before acting, and needing increased supervision. Hyperactivity/impulsivity seems to increase the likelihood of caregivers reporting AED behavioral side effects. The association between baseline psychological symptoms and AED behavioral side effects is consistent with recent data indicating that past psychiatric history predicts psychiatric and behavioral side effects in youths and adults. 30, 31 With assessment of baseline psychological functioning, providers can create algorithms for care based on whether hyperactivity/impulsivity is present. For example, if baseline hyperactivity/impulsivity is within normative limits at diagnosis, reported behavioral changes after AED initiation may be more confidently attributed to the AED as opposed to existing behavioral concerns in the child. Based on the F I G U R E 3 Behavioral side effect differences based on hyperactivity subscale cutoffs tolerability of the behavioral side effects, providers and families can make decisions to change the AED, reduce the dose while maintaining efficacy, or receive behavior management intervention from a behavioral health specialist. In contrast, children and adolescents with baseline clinical hyperactivity/impulsivity may be susceptible to having AED behavioral side effects. When behavioral side effects are reported in these children, providers should also consider AED efficacy, decreasing to a lower, therapeutic dose to minimize side effects, and proactively promote behavioral strategies to aid in managing baseline hyperactivity/ impulsivity, along with reported AED behavioral side effects. In effect, an AED change may not remediate concerns when baseline hyperactivity/impulsivity is present, particularly when the AED is controlling seizures, and symptoms may be best managed as a comorbidity. Evidence-based behavioral interventions to improve behavioral regulation, impulse control, 32 and minimization of AED behavioral effects are important first steps to improve tolerability and can be managed simultaneously in one behavioral intervention.
Limitations of the study should be considered when interpreting study findings. First, our model of integrated epilepsy and psychological care, along with our homogenous patient population, are relatively unique compared to other epilepsy clinics. This reduces generalizability to youths with more complex epilepsies, significant comorbid psychiatric/developmental disorders, or those receiving care outside a specialty epilepsy clinic. Relatedly, our established practice patterns for new onset epilepsy result in AEDs and epilepsy types that are highly linked (ie, valproic acid first line treatment for generalized epilepsy; carbamazepine first line treatment for localization-related epilepsy; levetiracetam first line treatment for unclassified epilepsy), so epilepsy types were not included in the analyses. Second, the length, need for scoring software, and cost of the BASC-2: PRS reduce its feasibility. The Vanderbilt may be a clinically expedient and affordable alternative to assess for hyperactivity, impulsivity, and behavioral disinhibition and may be familiar to many pediatric specialists. 32 Third, the study relied on caregiver perceptions of both baseline psychological functioning and AED behavioral side effects. Although this is not an ideal measurement due to some shared variance, the low correlations indicate detection of unique latent factors, and reliance on caregiver perceptions is inherent in pediatric epilepsy care. The BASC-2: PRS and the PESQ provide a standardized approach to enhance epilepsy care by distinguishing between baseline psychological functioning and AED behavioral side effects that warrant intervention. Future studies using prospective randomized clinical trials are needed to confirm these findings and to assist in disentangling baseline psychological screening from AED behavioral side effects, along with examining the underlying neurobiological mechanisms to explain why children with hyperactivity/impulsivity may be at risk of poor AED tolerability. For example, dopaminergic variation has been linked to levetiracetam behavioral side effects in adults. 33 Examination of the link between baseline psychological functioning and potential side effects of newer third generation AEDs (eg, clobazam, lacosamide), along with investigating epilepsy types, is also warranted. Furthermore, investigating the efficacy of behavioral interventions to enhance AED tolerability either through treating comorbidities or by teaching caregivers effective strategies to minimize the impact of behavioral side effects is needed.
Younger children seem to be more prone to experience AED behavioral side effects, and these are likely to be higher if youths with epilepsy have baseline difficulties with hyperactivity/impulsivity. 11 Younger children may have more difficulty than older children with AED tolerability, with valproic acid being a more challenging AED across the age spectrum. Baseline hyperactivity/impulsivity screening can be used as a precision medicine tool for AED selection. When baseline psychological symptoms are present, particularly hyperactivity/impulsivity, providers may consider avoiding AEDs with greater potential for psychotropic effects to increase tolerability for the patient and family early in the course of treatment, 11 along with decreasing the need for multiple AED trials due to problematic side effects. If unavoidable, caregivers may benefit from anticipatory guidance on managing behavioral side effects.
